Pyxis Oncology to Participate in September Investor and Industry Conferences

Rhea-AI Summary

Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing antibody-drug conjugate therapeutics, has announced its participation in three upcoming conferences in September 2025.

The company's CEO, Dr. Lara S. Sullivan, will participate in fireside chats at the 2025 Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8. Additionally, Pyxis will present at the 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit on September 9.

Webcasts for the investor conference presentations will be available on the company's investor relations website.

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences.

Investor Conferences

• 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET – Fireside chat and investor one-on-one meetings.
  
  
• H.C. Wainwright 27^th Annual Global Investment Conference, New York, NY, Monday, September 8, 10:30 a.m. ET – Fireside chat and investor one-on-one meetings.
  

Industry Conference

• 2^nd Annual ADC and Novel Conjugates Partnering and Investment Summit, Boston, MA, Tuesday, September 9, 3:20 p.m. ET – Company presentation (not webcast).
  

Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.

To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.

Pyxis Oncology Contact
Jitu Wadhane
Principal Financial and Accounting Officer
IR@pyxisoncology.com

Media
Molly Devlin
Real Chemistry
mdevlin@realchemistry.com

FAQ

When is Pyxis Oncology (PYXS) presenting at the Cantor Global Healthcare Conference 2025?

Pyxis Oncology will present at the Cantor Global Healthcare Conference on Wednesday, September 3, 2025, at 2:45 p.m. ET in New York, NY.

Where can I watch Pyxis Oncology's (PYXS) conference presentations?

Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page of Pyxis Oncology's investor relations website at ir.pyxisoncology.com.

What conferences will Pyxis Oncology (PYXS) attend in September 2025?

Pyxis Oncology will attend three conferences: the Cantor Global Healthcare Conference (Sept 3), H.C. Wainwright Global Investment Conference (Sept 8), and the 2nd Annual ADC and Novel Conjugates Summit (Sept 9).

Who will represent Pyxis Oncology (PYXS) at these conferences?

Dr. Lara S. Sullivan, who serves as President, Chief Executive Officer and Chief Medical Officer, will represent Pyxis Oncology at the conferences.